메뉴 건너뛰기




Volumn 3, Issue 3, 2014, Pages

Trial watch: Chemotherapy with immunogenic cell death inducers

Author keywords

ATP; Autophagy; Calreticulin; Dendritic cells; Epothilone B; HMGB1

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; IDARUBICIN; IMMUNOMODULATING AGENT; MITOXANTRONE; OXALIPLATIN;

EID: 84902504669     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27878     Document Type: Review
Times cited : (135)

References (134)
  • 1
    • 8144228952 scopus 로고    scopus 로고
    • Friends or foes-bipolareffects of the tumour stroma in cancer
    • PMID:15516957
    • Mueller MM, Fusenig NE. Friends or foes-bipolareffects of the tumour stroma in cancer. Nat RevCancer 2004; 4:839-49; PMID:15516957; http:// dx.doi.org/10.1038/nrc1477
    • (2004) Nat RevCancer , vol.4 , pp. 839-849
    • Mueller, M.M.1    Fusenig, N.E.2
  • 2
    • 33846531356 scopus 로고    scopus 로고
    • The tumour microenvironmentas a target for chemoprevention
    • PMID:17218951
    • Albini A, Sporn MB. The tumour microenvironmentas a target for chemoprevention. Nat Rev Cancer 2007; 7:139-47; PMID:17218951; http://dx.doi. org/10.1038/nrc2067
    • (2007) Nat Rev Cancer , vol.7 , pp. 139-147
    • Albini, A.1    Sporn, M.B.2
  • 3
    • 84876861350 scopus 로고    scopus 로고
    • Plasticity of tumourand immune cells: a source of heterogeneity anda cause for therapy resistance?
    • PMID:23535846
    • Hölzel M, Bovier A, Tüting T. Plasticity of tumourand immune cells: a source of heterogeneity anda cause for therapy resistance? Nat Rev Cancer 2013; 13:365-76; PMID:23535846; http://dx.doi. org/10.1038/nrc3498
    • (2013) Nat Rev Cancer , vol.13 , pp. 365-376
    • Hölzel, M.1    Bovier, A.2    Tüting, T.3
  • 4
    • 79953151458 scopus 로고    scopus 로고
    • Cancerimmunoediting: integrating immunity's roles incancer suppression and promotion
    • PMID:21436444
    • Schreiber RD, Old LJ, Smyth MJ. Cancerimmunoediting: integrating immunity's roles incancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi. org/10.1126/science.1203486
    • (2011) Science , vol.331 , pp. 1565-1570
    • Schreiber, R.D.1    Old, L.J.2    Smyth, M.J.3
  • 5
    • 2542430341 scopus 로고    scopus 로고
    • The three Esof cancer immunoediting
    • PMID:15032581
    • Dunn GP, Old LJ, Schreiber RD. The three Esof cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx.doi. org/10.1146/annurev.immunol.22.012703.104803
    • (2004) Annu Rev Immunol , vol.22 , pp. 329-360
    • Dunn, G.P.1    Old, L.J.2    Schreiber, R.D.3
  • 6
    • 0036852241 scopus 로고    scopus 로고
    • Cancer immunoediting: from immunosurveillanceto tumor escape
    • PMID:12407406
    • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillanceto tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ ni1102-991
    • (2002) Nat Immunol , vol.3 , pp. 991-998
    • Dunn, G.P.1    Bruce, A.T.2    Ikeda, H.3    Old, L.J.4    Schreiber, R.D.5
  • 7
    • 84884814550 scopus 로고    scopus 로고
    • Immunosurveillance as a regulator of tissuehomeostasis
    • PMID:23891238
    • Senovilla L, Galluzzi L, Zitvogel L, KroemerG. Immunosurveillance as a regulator of tissuehomeostasis. Trends Immunol 2013; 34:471-81; PMID:23891238; http://dx.doi.org/10.1016/j. it.2013.06.005
    • (2013) Trends Immunol , vol.34 , pp. 471-481
    • Senovilla, L.1    Galluzzi, L.2    Zitvogel, L.3    Kroemer, G.4
  • 10
    • 84880747672 scopus 로고    scopus 로고
    • Mechanism of action of conventional and targetedanticancer therapies: reinstating immunosurveillance
    • PMID:23890065
    • Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targetedanticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http:// dx.doi.org/10.1016/j.immuni.2013.06.014
    • (2013) Immunity , vol.39 , pp. 74-88
    • Zitvogel, L.1    Galluzzi, L.2    Smyth, M.J.3    Kroemer, G.4
  • 11
    • 84857789296 scopus 로고    scopus 로고
    • The secret al.y: immunostimulation by anticancerdrugs
    • PMID:22301798
    • Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret al.y: immunostimulation by anticancerdrugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/ nrd3626
    • (2012) Nat Rev Drug Discov , vol.11 , pp. 215-233
    • Galluzzi, L.1    Senovilla, L.2    Zitvogel, L.3    Kroemer, G.4
  • 14
    • 84872040888 scopus 로고    scopus 로고
    • Targeting the tumormicroenvironment for cancer therapy
    • PMID:23193058
    • Sounni NE, Noel A. Targeting the tumormicroenvironment for cancer therapy. Clin Chem 2013; 59:85-93; PMID:23193058; http://dx.doi. org/10.1373/clinchem.2012.185363
    • (2013) Clin Chem , vol.59 , pp. 85-93
    • Sounni, N.E.1    Noel, A.2
  • 15
    • 2442621619 scopus 로고    scopus 로고
    • Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    • PMID:15136787
    • Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev DrugDiscov 2004; 3:391-400; PMID:15136787; http:// dx.doi.org/10.1038/nrd1381
    • (2004) Nat Rev DrugDiscov , vol.3 , pp. 391-400
    • Ferrara, N.1    Hillan, K.J.2    Gerber, H.P.3    Novotny, W.4
  • 16
    • 84876872556 scopus 로고    scopus 로고
    • Dendriticcell inhibition correlates with survival of colorectalcancer patients on bevacizumab treatment
    • PMID:23243624
    • Michielsen AJ, Ryan EJ, O'Sullivan JN. Dendriticcell inhibition correlates with survival of colorectalcancer patients on bevacizumab treatment. Oncoimmunology 2012; 1:1445-7; PMID:23243624; http://dx.doi.org/10.4161/onci.21318
    • (2012) Oncoimmunology , vol.1 , pp. 1445-1447
    • Michielsen, A.J.1    Ryan, E.J.2    O'Sullivan, J.N.3
  • 21
    • 75249100054 scopus 로고    scopus 로고
    • Ipilimumab monotherapyin patients with pretreated advanced melanoma: arandomised, double-blind, multicentre, phase 2, dose-ranging study
    • PMID:20004617
    • Wolchok JD, Neyns B, Linette G, Negrier S, LutzkyJ, Thomas L, Waterfield W, Schadendorf D, SmylieM, Guthrie T Jr., et al. Ipilimumab monotherapyin patients with pretreated advanced melanoma: arandomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/ S1470-2045(09)70334-1
    • (2010) Lancet Oncol , vol.11 , pp. 155-164
    • Wolchok, J.D.1    Neyns, B.2    Linette, G.3    Negrier, S.4    Lutzky, J.5    Thomas, L.6    Waterfield, W.7    Schadendorf, D.8    Smylie, M.9    Guthrie Jr., T.10
  • 22
    • 84890285105 scopus 로고    scopus 로고
    • Inhibiting theinhibitors: Checkpoints blockade in solidtumors
    • PMID:24244910
    • Mavilio D, Lugli E. Inhibiting theinhibitors: Checkpoints blockade in solidtumors. Oncoimmunology 2013; 2:e26535; PMID:24244910; http://dx.doi.org/10.4161/ onci.26535
    • (2013) Oncoimmunology , vol.2
    • Mavilio, D.1    Lugli, E.2
  • 26
    • 35448977640 scopus 로고    scopus 로고
    • The use of FoxP3 as a biomarkerand prognostic factor for malignant human tumors
    • PMID:17932340
    • Schreiber TH. The use of FoxP3 as a biomarkerand prognostic factor for malignant human tumors. Cancer Epidemiol Biomarkers Prev 2007; 16:1931-4; PMID:17932340; http://dx.doi.org/10.1158/1055-9965.EPI-07-0396
    • (2007) Cancer Epidemiol Biomarkers Prev , vol.16 , pp. 1931-1934
    • Schreiber, T.H.1
  • 28
    • 84865782617 scopus 로고    scopus 로고
    • Optimizing cancer treatments toinduce an acute immune response: radiation Abscopaleffects, PAMPs, and DAMPs
    • PMID:22761465
    • Ludgate CM. Optimizing cancer treatments toinduce an acute immune response: radiation Abscopaleffects, PAMPs, and DAMPs. Clin Cancer Res 2012; 18:4522-5; PMID:22761465; http://dx.doi. org/10.1158/1078-0432.CCR-12-1175
    • (2012) Clin Cancer Res , vol.18 , pp. 4522-4525
    • Ludgate, C.M.1
  • 29
    • 84873421273 scopus 로고    scopus 로고
    • Abscopal but desirable: Thecontribution of immune responses to the efficacyof radiotherapy
    • PMID:22754758
    • Kroemer G, Zitvogel L. Abscopal but desirable: Thecontribution of immune responses to the efficacyof radiotherapy. Oncoimmunology 2012; 1:407-8; PMID:22754758; http://dx.doi.org/10.4161/ onci.20074
    • (2012) Oncoimmunology , vol.1 , pp. 407-408
    • Kroemer, G.1    Zitvogel, L.2
  • 30
    • 84861398744 scopus 로고    scopus 로고
    • Abscopal effectin a patient with melanoma
    • author reply 2035-6 PMID:22621637
    • Hiniker SM, Chen DS, Knox SJ. Abscopal effectin a patient with melanoma. N Engl J Med 2012; 366:2035-6, author reply 2035-6; PMID:22621637; http://dx.doi.org/10.1056/NEJMc1203984
    • (2012) N Engl J Med , vol.366 , pp. 2035-2036
    • Hiniker, S.M.1    Chen, D.S.2    Knox, S.J.3
  • 34
    • 84875944680 scopus 로고    scopus 로고
    • Chemotherapyand immunomodulation: from immunogenicchemotherapies to novel therapeutic strategies
    • PMID:23560368
    • Ghiringhelli F, Apetoh L. Chemotherapyand immunomodulation: from immunogenicchemotherapies to novel therapeutic strategies. FutureOncol 2013; 9:469-72; PMID:23560368; http:// dx.doi.org/10.2217/fon.12.207
    • (2013) FutureOncol , vol.9 , pp. 469-472
    • Ghiringhelli, F.1    Apetoh, L.2
  • 36
    • 84875552922 scopus 로고    scopus 로고
    • Immunogenic cell death in cancertherapy
    • PMID:23157435
    • Kroemer G, Galluzzi L, Kepp O, ZitvogelL. Immunogenic cell death in cancertherapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008
    • (2013) Annu Rev Immunol , vol.31 , pp. 51-72
    • Kroemer, G.1    Galluzzi, L.2    Kepp, O.3    Zitvogel, L.4
  • 37
    • 84870206960 scopus 로고    scopus 로고
    • Mitochondria: master regulators of danger signalling
    • PMID:23175281
    • Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev MolCell Biol 2012; 13:780-8; PMID:23175281; http:// dx.doi.org/10.1038/nrm3479
    • (2012) Nat Rev MolCell Biol , vol.13 , pp. 780-788
    • Galluzzi, L.1    Kepp, O.2    Kroemer, G.3
  • 38
    • 84890034987 scopus 로고    scopus 로고
    • Dangersignalling during cancer cell death: origins, plasticityand regulation
    • PMID:23686135
    • Garg AD, Martin S, Golab J, Agostinis P. Dangersignalling during cancer cell death: origins, plasticityand regulation. Cell Death Differ 2014; 21:26-38; PMID:23686135; http://dx.doi.org/10.1038/ cdd.2013.48
    • (2014) Cell Death Differ , vol.21 , pp. 26-38
    • Garg, A.D.1    Martin, S.2    Golab, J.3    Agostinis, P.4
  • 39
    • 84881668150 scopus 로고    scopus 로고
    • Cancerimmunogenicity, danger signals, and DAMPs: what, when, and how?
    • PMID:23900966
    • Garg AD, Dudek AM, Agostinis P. Cancerimmunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 2013; 39:355-67; PMID:23900966; http://dx.doi.org/10.1002/ biof.1125
    • (2013) Biofactors , vol.39 , pp. 355-367
    • Garg, A.D.1    Dudek, A.M.2    Agostinis, P.3
  • 44
    • 79551523389 scopus 로고    scopus 로고
    • Cyclophosphamide synergizeswith type I interferons through systemic dendriticcell reactivation and induction of immunogenictumor apoptosis
    • PMID:21156650
    • Schiavoni G, Sistigu A, Valentini M, Mattei F, SestiliP, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. Cyclophosphamide synergizeswith type I interferons through systemic dendriticcell reactivation and induction of immunogenictumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788
    • (2011) Cancer Res , vol.71 , pp. 768-778
    • Schiavoni, G.1    Sistigu, A.2    Valentini, M.3    Mattei, F.4    Sestili, P.5    Spadaro, F.6    Sanchez, M.7    Lorenzi, S.8    D'Urso, M.T.9    Belardelli, F.10
  • 47
    • 79960406242 scopus 로고    scopus 로고
    • Human tumor cellskilled by anthracyclines induce a tumor-specificimmune response
    • PMID:21602432
    • Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spísek R. Human tumor cellskilled by anthracyclines induce a tumor-specificimmune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950
    • (2011) Cancer Res , vol.71 , pp. 4821-4833
    • Fucikova, J.1    Kralikova, P.2    Fialova, A.3    Brtnicky, T.4    Rob, L.5    Bartunkova, J.6    Spísek, R.7
  • 48
    • 79952533264 scopus 로고    scopus 로고
    • Restoration of theimmunogenicity of cisplatin-induced cancer celldeath by endoplasmic reticulum stress
    • PMID:21151176
    • Martins I, Kepp O, Schlemmer F, AdjemianS, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of theimmunogenicity of cisplatin-induced cancer celldeath by endoplasmic reticulum stress. Oncogene 2011; 30:1147-58; PMID:21151176; http://dx.doi. org/10.1038/onc.2010.500
    • (2011) Oncogene , vol.30 , pp. 1147-1158
    • Martins, I.1    Kepp, O.2    Schlemmer, F.3    Adjemian, S.4    Tailler, M.5    Shen, S.6    Michaud, M.7    Menger, L.8    Gdoura, A.9    Tajeddine, N.10
  • 54
    • 11144242211 scopus 로고    scopus 로고
    • Timeline: Chemotherapyand the war on cancer
    • PMID:15630416
    • Chabner BA, Roberts TG Jr. Timeline: Chemotherapyand the war on cancer. Nat Rev Cancer 2005; 5:65-72; PMID:15630416; http://dx.doi.org/10.1038/ nrc1529
    • (2005) Nat Rev Cancer , vol.5 , pp. 65-72
    • Chabner, B.A.1    Roberts Jr., T.G.2
  • 55
    • 84878573270 scopus 로고    scopus 로고
    • Sequentialchemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed byalemtuzumab consolidation is effective in T-cellprolymphocytic leukemia
    • PMID:23512246
    • Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, et al. Sequentialchemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed byalemtuzumab consolidation is effective in T-cellprolymphocytic leukemia. Cancer 2013; 119:2258-67; PMID:23512246; http://dx.doi.org/10.1002/ cncr.27972
    • (2013) Cancer , vol.119 , pp. 2258-2267
    • Hopfinger, G.1    Busch, R.2    Pflug, N.3    Weit, N.4    Westermann, A.5    Fink, A.M.6    Cramer, P.7    Reinart, N.8    Winkler, D.9    Fingerle-Rowson, G.10
  • 56
    • 84877814153 scopus 로고    scopus 로고
    • Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and functionin melanoma patients vaccinated with HLA-classI peptides: impact on the antigen-specific T cellresponse
    • PMID:23589107
    • Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, et al. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and functionin melanoma patients vaccinated with HLA-classI peptides: impact on the antigen-specific T cellresponse. Cancer Immunol Immunother 2013; 62:897-908; PMID:23589107; http://dx.doi. org/10.1007/s00262-013-1397-7
    • (2013) Cancer Immunol Immunother , vol.62 , pp. 897-908
    • Camisaschi, C.1    Filipazzi, P.2    Tazzari, M.3    Casati, C.4    Beretta, V.5    Pilla, L.6    Patuzzo, R.7    Maurichi, A.8    Cova, A.9    Maio, M.10
  • 57
    • 84891373760 scopus 로고    scopus 로고
    • Tecemotide (L-BLP25) versus placebo afterchemoradiotherapy for stage III non-small-celllung cancer (START): a randomised, doubleblind, phase 3 trial
    • START trialteam PMID:24331154
    • Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, CiuleanuTE, Bosquée L, Trigo JM, et al.; START trialteam. Tecemotide (L-BLP25) versus placebo afterchemoradiotherapy for stage III non-small-celllung cancer (START): a randomised, doubleblind, phase 3 trial. Lancet Oncol 2014; 15:59-68; PMID:24331154; http://dx.doi.org/10.1016/ S1470-2045(13)70510-2
    • (2014) Lancet Oncol , vol.15 , pp. 59-68
    • Butts, C.1    Socinski, M.A.2    Mitchell, P.L.3    Thatcher, N.4    Havel, L.5    Krzakowski, M.6    Nawrocki, S.7    Ciuleanu, T.E.8    Bosquée, L.9    Trigo, J.M.10
  • 59
    • 84886943675 scopus 로고    scopus 로고
    • Phase I clinical trial combining imatinibmesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinibmesylate
    • PMID:23525192
    • Pautier P, Locher C, Robert C, Deroussent A, FlamentC, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, et al. Phase I clinical trial combining imatinibmesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinibmesylate. Oncoimmunology 2013; 2:e23079; PMID:23525192; http://dx.doi.org/10.4161/ onci.23079
    • (2013) Oncoimmunology , vol.2
    • Pautier, P.1    Locher, C.2    Robert, C.3    Deroussent, A.4    Flament, C.5    Le Cesne, A.6    Rey, A.7    Bahleda, R.8    Ribrag, V.9    Soria, J.C.10
  • 60
    • 84871979382 scopus 로고    scopus 로고
    • Phase I and clinicalpharmacology study of bevacizumab, sorafenib, andlow-dose cyclophosphamide in children and youngadults with refractory/recurrent solid tumors
    • PMID:23143218
    • Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, FurmanWL, McGregor LM, et al. Phase I and clinicalpharmacology study of bevacizumab, sorafenib, andlow-dose cyclophosphamide in children and youngadults with refractory/recurrent solid tumors. ClinCancer Res 2013; 19:236-46; PMID:23143218; http://dx.doi.org/10.1158/1078-0432.CCR-12-1897
    • (2013) ClinCancer Res , vol.19 , pp. 236-246
    • Navid, F.1    Baker, S.D.2    McCarville, M.B.3    Stewart, C.F.4    Billups, C.A.5    Wu, J.6    Davidoff, A.M.7    Spunt, S.L.8    Furman, W.L.9    McGregor, L.M.10
  • 61
    • 84872135803 scopus 로고    scopus 로고
    • A phase 1bstudy of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patientswith EpCAM-positive advanced solid tumors
    • PMID:23320927
    • Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, StewartS, Harter J, Henslee-Downey J, et al. A phase 1bstudy of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patientswith EpCAM-positive advanced solid tumors. BMCCancer 2013; 13:20; PMID:23320927; http:// dx.doi.org/10.1186/1471-2407-13-20
    • (2013) BMCCancer , vol.13 , pp. 20
    • Connor, J.P.1    Cristea, M.C.2    Lewis, N.L.3    Lewis, L.D.4    Komarnitsky, P.B.5    Mattiacci, M.R.6    Felder, M.7    Stewart, S.8    Harter, J.9    Henslee-Downey, J.10
  • 62
    • 84885174214 scopus 로고    scopus 로고
    • A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advancedcolorectal cancer
    • PMID:24022191
    • Kelley RK, Hwang J, Magbanua MJ, Watt L, BeumerJH, Christner SM, Baruchel S, Wu B, Fong L, YehBM, et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advancedcolorectal cancer. Br J Cancer 2013; 109:1725-34; PMID:24022191; http://dx.doi.org/10.1038/ bjc.2013.553
    • (2013) Br J Cancer , vol.109 , pp. 1725-1734
    • Kelley, R.K.1    Hwang, J.2    Magbanua, M.J.3    Watt, L.4    Beumer, J.H.5    Christner, S.M.6    Baruchel, S.7    Wu, B.8    Fong, L.9    Yeh, B.M.10
  • 63
    • 84891587587 scopus 로고    scopus 로고
    • Randomized, multicenter, open-label studyof oxaliplatin plus fluorouracil/leucovorin versusdoxorubicin as palliative chemotherapy in patientswith advanced hepatocellular carcinoma from Asia
    • PMID:23980077
    • Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, ZhouY, et al. Randomized, multicenter, open-label studyof oxaliplatin plus fluorouracil/leucovorin versusdoxorubicin as palliative chemotherapy in patientswith advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31:3501-8; PMID:23980077; http://dx.doi.org/10.1200/JCO.2012.44.5643
    • (2013) J Clin Oncol , vol.31 , pp. 3501-3508
    • Qin, S.1    Bai, Y.2    Lim, H.Y.3    Thongprasert, S.4    Chao, Y.5    Fan, J.6    Yang, T.S.7    Bhudhisawasdi, V.8    Kang, W.K.9    Zhou, Y.10
  • 64
    • 84873170055 scopus 로고    scopus 로고
    • Neoadjuvant and adjuvantchemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexatein non-metastatic osteosarcoma of the extremities: aphase II trial in Japan
    • PMID:23433444
    • Kudawara I, Aoki Y, Ueda T, Araki N, Naka N, Nakanishi H, Matsumine A, Ieguchi M, MoriS, Myoui A, et al. Neoadjuvant and adjuvantchemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexatein non-metastatic osteosarcoma of the extremities: aphase II trial in Japan. J Chemother 2013; 25:41-8; PMID:23433444; http://dx.doi.org/10.1179/197394 7812Y.0000000055
    • (2013) J Chemother , vol.25 , pp. 41-48
    • Kudawara, I.1    Aoki, Y.2    Ueda, T.3    Araki, N.4    Naka, N.5    Nakanishi, H.6    Matsumine, A.7    Ieguchi, M.8    Mori, S.9    Myoui, A.10
  • 65
    • 84878630425 scopus 로고    scopus 로고
    • A phase IItrial of androgen deprivation therapy (ADT) pluschemotherapy as initial treatment for local failuresor advanced prostate cancer
    • PMID:23604530
    • Amato R, Stepankiw M, Gonzales P. A phase IItrial of androgen deprivation therapy (ADT) pluschemotherapy as initial treatment for local failuresor advanced prostate cancer. Cancer ChemotherPharmacol 2013; 71:1629-34; PMID:23604530; http://dx.doi.org/10.1007/s00280-013-2163-4
    • (2013) Cancer ChemotherPharmacol , vol.71 , pp. 1629-1634
    • Amato, R.1    Stepankiw, M.2    Gonzales, P.3
  • 66
    • 84872019367 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin as third-linechemotherapy in patients with metastatic transitionalcell carcinoma of urothelial tract: results of a phase IIstudy
    • PMID:23307245
    • Rozzi A, Santini D, Salerno M, Bordin F, Mancuso A, Minniti G, Nardoni C, Corona M, Falbo PT, RecineF, et al. Pegylated liposomal doxorubicin as third-linechemotherapy in patients with metastatic transitionalcell carcinoma of urothelial tract: results of a phase IIstudy. Med Oncol 2013; 30:407; PMID:23307245; http://dx.doi.org/10.1007/s12032-012-0407-5
    • (2013) Med Oncol , vol.30 , pp. 407
    • Rozzi, A.1    Santini, D.2    Salerno, M.3    Bordin, F.4    Mancuso, A.5    Minniti, G.6    Nardoni, C.7    Corona, M.8    Falbo, P.T.9    Recine, F.10
  • 67
    • 84872981467 scopus 로고    scopus 로고
    • A phase 2 clinical trial of sequential neoadjuvantchemotherapy with ifosfamide, doxorubicin, andgemcitabine followed by cisplatin, gemcitabine, andifosfamide in locally advanced urothelial cancer: finalresults
    • PMID:22914978
    • Siefker-Radtke AO, Dinney CP, Shen Y, WilliamsDL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvantchemotherapy with ifosfamide, doxorubicin, andgemcitabine followed by cisplatin, gemcitabine, andifosfamide in locally advanced urothelial cancer: finalresults. Cancer 2013; 119:540-7; PMID:22914978; http://dx.doi.org/10.1002/cncr.27751
    • (2013) Cancer , vol.119 , pp. 540-547
    • Siefker-Radtke, A.O.1    Dinney, C.P.2    Shen, Y.3    Williams, D.L.4    Kamat, A.M.5    Grossman, H.B.6    Millikan, R.E.7
  • 68
    • 84878217873 scopus 로고    scopus 로고
    • A phase I study ofoxaliplatin and doxorubicin in pediatric patients withrelapsed or refractory extracranial non-hematopoieticsolid tumors
    • PMID:23335436
    • Mascarenhas L, Malogolowkin M, Armenian SH, Sposto R, Venkatramani R. A phase I study ofoxaliplatin and doxorubicin in pediatric patients withrelapsed or refractory extracranial non-hematopoieticsolid tumors. Pediatr Blood Cancer 2013; 60:1103-7; PMID:23335436; http://dx.doi.org/10.1002/ pbc.24471
    • (2013) Pediatr Blood Cancer , vol.60 , pp. 1103-1107
    • Mascarenhas, L.1    Malogolowkin, M.2    Armenian, S.H.3    Sposto, R.4    Venkatramani, R.5
  • 69
    • 84876992498 scopus 로고    scopus 로고
    • Epirubicin, oxaliplatin, and capecitabine with or without panitumumabfor patients with previously untreated advancedoesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    • PMID:23594787
    • Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumabfor patients with previously untreated advancedoesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:481-9; PMID:23594787; http://dx.doi.org/10.1016/ S1470-2045(13)70096-2
    • (2013) Lancet Oncol , vol.14 , pp. 481-489
    • Waddell, T.1    Chau, I.2    Cunningham, D.3    Gonzalez, D.4    Okines, A.F.5    Okines, C.6    Wotherspoon, A.7    Saffery, C.8    Middleton, G.9    Wadsley, J.10
  • 70
    • 84896377353 scopus 로고    scopus 로고
    • A phase I trial of bortezomibin combination with epirubicin, carboplatinand capecitabine (ECarboX) in advancedoesophagogastric adenocarcinoma
    • In press, PMID:23665866
    • Turkington RC, Purcell C, James CR, Millar J, Napier E, Law D, Gallagher R, Morris M, Wilson RH, Eatock MM. A phase I trial of bortezomibin combination with epirubicin, carboplatinand capecitabine (ECarboX) in advancedoesophagogastric adenocarcinoma. Invest New Drugs 2013; In press; PMID:23665866; http://dx.doi. org/10.1007/s10637-013-9970-7.
    • (2013) Invest New Drugs
    • Turkington, R.C.1    Purcell, C.2    James, C.R.3    Millar, J.4    Napier, E.5    Law, D.6    Gallagher, R.7    Morris, M.8    Wilson, R.H.9    Eatock, M.M.10
  • 71
    • 84874108659 scopus 로고    scopus 로고
    • Methotrexate-paclitaxelepirubicin-carboplatin as second-line chemotherapyin patients with metastatic transitional cellcarcinoma of the bladder pretreated with cisplatingemcitabine: a phase II study
    • PMID:22897883
    • Halim A, Abotouk N. Methotrexate-paclitaxelepirubicin-carboplatin as second-line chemotherapyin patients with metastatic transitional cellcarcinoma of the bladder pretreated with cisplatingemcitabine: a phase II study. Asia Pac J Clin Oncol 2013; 9:60-5; PMID:22897883; http://dx.doi. org/10.1111/j.1743-7563.2012.01554.x
    • (2013) Asia Pac J Clin Oncol , vol.9 , pp. 60-65
    • Halim, A.1    Abotouk, N.2
  • 72
    • 84884154021 scopus 로고    scopus 로고
    • Phase I-II clinicaltrial of oxaliplatin, fludarabine, cytarabine, andrituximab therapy in aggressive relapsed/refractorychronic lymphocytic leukemia or Richter syndrome
    • Chronic LymphocyticLeukemia Research Consortium PMID:23810245
    • Tsimberidou AM, Wierda WG, Wen S, PlunkettW, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ; Chronic LymphocyticLeukemia Research Consortium. Phase I-II clinicaltrial of oxaliplatin, fludarabine, cytarabine, andrituximab therapy in aggressive relapsed/refractorychronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013; 13:568-74; PMID:23810245; http://dx.doi.org/10.1016/j. clml.2013.03.012
    • (2013) Clin Lymphoma Myeloma Leuk , vol.13 , pp. 568-574
    • Tsimberidou, A.M.1    Wierda, W.G.2    Wen, S.3    Plunkett, W.4    O'Brien, S.5    Kipps, T.J.6    Jones, J.A.7    Badoux, X.8    Kantarjian, H.9    Keating, M.J.10
  • 73
    • 84914670329 scopus 로고    scopus 로고
    • PhaseII clinical trial of oxaliplatin and bevacizumabin refractory germ cell tumors
    • In press, PMID:23388561
    • Jain A, Brames MJ, Vaughn DJ, Einhorn LH. PhaseII clinical trial of oxaliplatin and bevacizumabin refractory germ cell tumors. Am J Clin Oncol 2013; In press; PMID:23388561; http://dx.doi. org/10.1097/COC.0b013e31827de90d.
    • (2013) Am J Clin Oncol
    • Jain, A.1    Brames, M.J.2    Vaughn, D.J.3    Einhorn, L.H.4
  • 75
    • 84892572211 scopus 로고    scopus 로고
    • Efficacy and safety of docetaxel combinedwith oxaliplatin as a neoadjuvant chemotherapyregimen for Chinese triple-negative local advancedbreast cancer patients. A prospective, open, andunicentric Phase II clinical trial
    • PMID:22868245
    • Fei F, Chen C, Xue J, Di GH, Lu JS, Liu GY, ShaoZM, Wu J. Efficacy and safety of docetaxel combinedwith oxaliplatin as a neoadjuvant chemotherapyregimen for Chinese triple-negative local advancedbreast cancer patients. A prospective, open, andunicentric Phase II clinical trial. Am J Clin Oncol 2013; 36:545-51; PMID:22868245; http://dx.doi. org/10.1097/COC.0b013e31825d5317
    • (2013) Am J Clin Oncol , vol.36 , pp. 545-551
    • Fei, F.1    Chen, C.2    Xue, J.3    Di, G.H.4    Lu, J.S.5    Liu, G.Y.6    Shao, Z.M.7    Wu, J.8
  • 76
    • 84887153000 scopus 로고    scopus 로고
    • A multicenter phaseII study of docetaxel, oxaliplatin, and bevacizumabin first-line therapy for unresectable locally advancedor metastatic non-squamous cell histology nonsmall-cell lung cancer (NSCLC)
    • PMID:24057043
    • Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH. A multicenter phaseII study of docetaxel, oxaliplatin, and bevacizumabin first-line therapy for unresectable locally advancedor metastatic non-squamous cell histology nonsmall-cell lung cancer (NSCLC). Cancer ChemotherPharmacol 2013; 72:1103-10; PMID:24057043; http://dx.doi.org/10.1007/s00280-013-2301-z
    • (2013) Cancer ChemotherPharmacol , vol.72 , pp. 1103-1110
    • Raez, L.E.1    Santos, E.S.2    Webb, R.T.3    Wade, J.4    Brito, R.A.5    Karr, M.6    Kennah, A.7    Childs, B.H.8
  • 77
    • 84873719135 scopus 로고    scopus 로고
    • A randomised multicentre phaseII study with cisplatin/docetaxel vs oxaliplatin/ docetaxel as first-line therapy in patients withadvanced or metastatic non-small cell lung cancer
    • PMID:23329236
    • Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, BanatAG, Brueck P, et al. A randomised multicentre phaseII study with cisplatin/docetaxel vs oxaliplatin/ docetaxel as first-line therapy in patients withadvanced or metastatic non-small cell lung cancer. Br J Cancer 2013; 108:265-70; PMID:23329236; http://dx.doi.org/10.1038/bjc.2012.555
    • (2013) Br J Cancer , vol.108 , pp. 265-270
    • Atmaca, A.1    Al-Batran, S.E.2    Werner, D.3    Pauligk, C.4    Güner, T.5    Koepke, A.6    Bernhard, H.7    Wenzel, T.8    Banat, A.G.9    Brueck, P.10
  • 78
    • 84881252044 scopus 로고    scopus 로고
    • Longtermfollow-up of a phase III study comparingradiotherapy with or without weekly oxaliplatin forlocoregionally advanced nasopharyngeal carcinoma
    • PMID:23661293
    • Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, Hou X, Zhao HY, Huang Y, Fang WF, et al. Longtermfollow-up of a phase III study comparingradiotherapy with or without weekly oxaliplatin forlocoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2013; 24:2131-6; PMID:23661293; http://dx.doi.org/10.1093/annonc/mdt163
    • (2013) Ann Oncol , vol.24 , pp. 2131-2136
    • Wu, X.1    Huang, P.Y.2    Peng, P.J.3    Lu, L.X.4    Han, F.5    Wu, S.X.6    Hou, X.7    Zhao, H.Y.8    Huang, Y.9    Fang, W.F.10
  • 79
    • 84884245742 scopus 로고    scopus 로고
    • A phase II trial of oxaliplatin plus S-1 asa first-line chemotherapy for patients with advancedgastric cancer
    • PMID:24034092
    • Yang L, Song Y, Zhou AP, Qin Q, Chi Y, Huang J, Wang JW. A phase II trial of oxaliplatin plus S-1 asa first-line chemotherapy for patients with advancedgastric cancer. Chin Med J (Engl) 2013; 126:3470-4; PMID:24034092
    • (2013) Chin Med J (Engl) , vol.126 , pp. 3470-3474
    • Yang, L.1    Song, Y.2    Zhou, A.P.3    Qin, Q.4    Chi, Y.5    Huang, J.6    Wang, J.W.7
  • 80
    • 84875412388 scopus 로고    scopus 로고
    • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatmentof metastatic esophagogastric adenocarcinomas
    • PMID:23485624
    • Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, ConklingP, Favaro J, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatmentof metastatic esophagogastric adenocarcinomas. Oncologist 2013; 18:271-2; PMID:23485624; http://dx.doi.org/10.1634/theoncologist.2012-0404
    • (2013) Oncologist , vol.18 , pp. 271-272
    • Uronis, H.E.1    Bendell, J.C.2    Altomare, I.3    Blobe, G.C.4    Hsu, S.D.5    Morse, M.A.6    Pang, H.7    Zafar, S.Y.8    Conkling, P.9    Favaro, J.10
  • 81
    • 84894183457 scopus 로고    scopus 로고
    • Docetaxel, oxaliplatin and capecitabine (TEX regimen) inpatients with metastatic gastric or gastro-esophagealcancer: Results of a multicenter phase I/II study
    • In press; PMID:24024696
    • Stein A, Arnold D, Thuss-Patience PC, MoehlerM, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ. Docetaxel, oxaliplatin and capecitabine (TEX regimen) inpatients with metastatic gastric or gastro-esophagealcancer: Results of a multicenter phase I/II study. Acta Oncol 2013; In press; PMID:24024696; http:// dx.doi.org/10.3109/0284186X.2013.833346.
    • (2013) Acta Oncol
    • Stein, A.1    Arnold, D.2    Thuss-Patience, P.C.3    Moehler, M.4    Grothe, W.5    Seufferlein, T.6    Reinacher-Schick, A.7    Geissler, M.8    Hofheinz, R.D.9    Schmoll, H.J.10
  • 82
    • 84887185245 scopus 로고    scopus 로고
    • Phase I clinicaland pharmacokinetic/pharmacogenetic study ofa triplet regimen of S-1/irinotecan/oxaliplatin inpatients with metastatic colorectal or gastric cancer
    • PMID:23982118
    • Park SR, Hong YS, Lim HS, Seong MW, KongSY, Kim SY, Park YI, Jung KH. Phase I clinicaland pharmacokinetic/pharmacogenetic study ofa triplet regimen of S-1/irinotecan/oxaliplatin inpatients with metastatic colorectal or gastric cancer. Cancer Chemother Pharmacol 2013; 72:953-64; PMID:23982118; http://dx.doi.org/10.1007/ s00280-013-2272-0
    • (2013) Cancer Chemother Pharmacol , vol.72 , pp. 953-964
    • Park, S.R.1    Hong, Y.S.2    Lim, H.S.3    Seong, M.W.4    Kong, S.Y.5    Kim, S.Y.6    Park, Y.I.7    Jung, K.H.8
  • 83
    • 84885387187 scopus 로고    scopus 로고
    • Aphase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgeryand adjuvant S-1 chemotherapy in potentiallyresectable gastric or gastroesophageal junctionadenocarcinoma
    • PMID:23921575
    • Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, ParkYS, Kim HJ, Jung HY, Lee GH, Kim KC, et al. Aphase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgeryand adjuvant S-1 chemotherapy in potentiallyresectable gastric or gastroesophageal junctionadenocarcinoma. Cancer Chemother Pharmacol 2013; 72:815-23; PMID:23921575; http://dx.doi. org/10.1007/s00280-013-2257-z
    • (2013) Cancer Chemother Pharmacol , vol.72 , pp. 815-823
    • Park, I.1    Ryu, M.H.2    Choi, Y.H.3    Kang, H.J.4    Yook, J.H.5    Park, Y.S.6    Kim, H.J.7    Jung, H.Y.8    Lee, G.H.9    Kim, K.C.10
  • 84
    • 84874150344 scopus 로고    scopus 로고
    • Prospective, open, multicentrephase I/II trial to assess safety and efficacyof neoadjuvant radiochemotherapy with docetaxeland oxaliplatin in patients with adenocarcinomaof the oesophagogastric junction
    • PMID:23394629
    • Moehler M, Gockel I, Roessler HP, Arnold D, Trarbach T, Thomaidis T, Klautke G, Rödel C, Brenner B, Lang H, et al. Prospective, open, multicentrephase I/II trial to assess safety and efficacyof neoadjuvant radiochemotherapy with docetaxeland oxaliplatin in patients with adenocarcinomaof the oesophagogastric junction. BMC Cancer 2013; 13:75; PMID:23394629; http://dx.doi. org/10.1186/1471-2407-13-75
    • (2013) BMC Cancer , vol.13 , pp. 75
    • Moehler, M.1    Gockel, I.2    Roessler, H.P.3    Arnold, D.4    Trarbach, T.5    Thomaidis, T.6    Klautke, G.7    Rödel, C.8    Brenner, B.9    Lang, H.10
  • 86
    • 84888588300 scopus 로고    scopus 로고
    • Phase I study of sunitinib plus capecitabine/ cisplatin or capecitabine/oxaliplatin in advancedgastric cancer
    • PMID:24091982
    • Lee KW, Park SR, Oh DY, Park YI, KhosravanR, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, et al. Phase I study of sunitinib plus capecitabine/ cisplatin or capecitabine/oxaliplatin in advancedgastric cancer. Invest New Drugs 2013; 31:1547-58; PMID:24091982; http://dx.doi.org/10.1007/ s10637-013-0032-y
    • (2013) Invest New Drugs , vol.31 , pp. 1547-1558
    • Lee, K.W.1    Park, S.R.2    Oh, D.Y.3    Park, Y.I.4    Khosravan, R.5    Lin, X.6    Lee, S.Y.7    Roh, E.J.8    Valota, O.9    Lechuga, M.J.10
  • 87
    • 84892786410 scopus 로고    scopus 로고
    • Arandomized phase II study of weekly docetaxel/ cisplatin versus weekly docetaxel/oxaliplatin asfirst-line therapy for patients with advanced gastriccancer
    • PMID:24202666
    • Kim YS, Sym SJ, Park SH, Park I, Hong J, AhnHK, Park J, Cho EK, Lee WK, Chung M, et al. Arandomized phase II study of weekly docetaxel/ cisplatin versus weekly docetaxel/oxaliplatin asfirst-line therapy for patients with advanced gastriccancer. Cancer Chemother Pharmacol 2014; 73:163-9; PMID:24202666; http://dx.doi.org/10.1007/ s00280-013-2334-3
    • (2014) Cancer Chemother Pharmacol , vol.73 , pp. 163-169
    • Kim, Y.S.1    Sym, S.J.2    Park, S.H.3    Park, I.4    Hong, J.5    Ahn, H.K.6    Park, J.7    Cho, E.K.8    Lee, W.K.9    Chung, M.10
  • 90
    • 84884819988 scopus 로고    scopus 로고
    • A Phase Istudy of the combination of oxaliplatin/docetaxeland vandetanib for the treatment of advancedgastroesophageal cancer
    • PMID:23553066
    • Halmos B, Jia Y, Bokar JA, Fu P, Adelstein DJ, Juergens R, Rodal MB, Dowlati A. A Phase Istudy of the combination of oxaliplatin/docetaxeland vandetanib for the treatment of advancedgastroesophageal cancer. Invest New Drugs 2013; 31:1244-50; PMID:23553066; http://dx.doi. org/10.1007/s10637-013-9945-8
    • (2013) Invest New Drugs , vol.31 , pp. 1244-1250
    • Halmos, B.1    Jia, Y.2    Bokar, J.A.3    Fu, P.4    Adelstein, D.J.5    Juergens, R.6    Rodal, M.B.7    Dowlati, A.8
  • 91
    • 84878876390 scopus 로고    scopus 로고
    • A two-cohort phase I study of weeklyoxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy forunresectable pancreatic carcinoma
    • PMID:22547007
    • Raftery L, Tepper JE, Goldberg RM, BlackstockAW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weeklyoxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy forunresectable pancreatic carcinoma. Am J Clin Oncol 2013; 36:250-3; PMID:22547007; http://dx.doi. org/10.1097/COC.0b013e3182467f22
    • (2013) Am J Clin Oncol , vol.36 , pp. 250-253
    • Raftery, L.1    Tepper, J.E.2    Goldberg, R.M.3    Blackstock, A.W.4    Aklilu, M.5    Bernard, S.A.6    Ivanova, A.7    Davies, J.M.8    O'Neil, B.H.9
  • 92
    • 84880921318 scopus 로고    scopus 로고
    • A phase Istudy of sorafenib, oxaliplatin and 2 days of high dosecapecitabine in advanced pancreatic and biliary tractcancer: a Wisconsin oncology network study
    • PMID:23263993
    • LoConte NK, Holen KD, Schelman WR, MulkerinDL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, et al. A phase Istudy of sorafenib, oxaliplatin and 2 days of high dosecapecitabine in advanced pancreatic and biliary tractcancer: a Wisconsin oncology network study. InvestNew Drugs 2013; 31:943-8; PMID:23263993; http://dx.doi.org/10.1007/s10637-012-9916-5
    • (2013) InvestNew Drugs , vol.31 , pp. 943-948
    • LoConte, N.K.1    Holen, K.D.2    Schelman, W.R.3    Mulkerin, D.L.4    Deming, D.A.5    Hernan, H.R.6    Traynor, A.M.7    Goggins, T.8    Groteluschen, D.9    Oettel, K.10
  • 93
    • 84880573171 scopus 로고    scopus 로고
    • Amulti-institutional phase 2 study of neoadjuvantgemcitabine and oxaliplatin with radiation therapyin patients with pancreatic cancer
    • PMID:23720019
    • Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, et al. Amulti-institutional phase 2 study of neoadjuvantgemcitabine and oxaliplatin with radiation therapyin patients with pancreatic cancer. Cancer 2013; 119:2692-700; PMID:23720019; http://dx.doi. org/10.1002/cncr.28117
    • (2013) Cancer , vol.119 , pp. 2692-2700
    • Kim, E.J.1    Ben-Josef, E.2    Herman, J.M.3    Bekaii-Saab, T.4    Dawson, L.A.5    Griffith, K.A.6    Francis, I.R.7    Greenson, J.K.8    Simeone, D.M.9    Lawrence, T.S.10
  • 94
    • 84884744581 scopus 로고    scopus 로고
    • AMulticenter Phase II Trial of Gemcitabine PlusOxaliplatin in Unresectable Gallbladder Cancer
    • PMID:24073318
    • Woo SM, Lee SH, Yoo JW, Yang KY, Seo JG, ParkJK, Hwang JH, Lee WJ, Ryu JK, Kim YT, et al. AMulticenter Phase II Trial of Gemcitabine PlusOxaliplatin in Unresectable Gallbladder Cancer. Gut Liver 2013; 7:594-8; PMID:24073318; http:// dx.doi.org/10.5009/gnl.2013.7.5.594
    • (2013) Gut Liver , vol.7 , pp. 594-598
    • Woo, S.M.1    Lee, S.H.2    Yoo, J.W.3    Yang, K.Y.4    Seo, J.G.5    Park, J.K.6    Hwang, J.H.7    Lee, W.J.8    Ryu, J.K.9    Kim, Y.T.10
  • 96
    • 84888309055 scopus 로고    scopus 로고
    • A phase 2 study of oxaliplatin combined withcontinuous infusion topotecan for patients withpreviously treated ovarian cancer
    • PMID:24172094
    • Stein SM, Tiersten A, Hochster HS, Blank SV, PothuriB, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, et al. A phase 2 study of oxaliplatin combined withcontinuous infusion topotecan for patients withpreviously treated ovarian cancer. Int J GynecolCancer 2013; 23:1577-82; PMID:24172094; http:// dx.doi.org/10.1097/IGC.0b013e3182a809e0
    • (2013) Int J GynecolCancer , vol.23 , pp. 1577-1582
    • Stein, S.M.1    Tiersten, A.2    Hochster, H.S.3    Blank, S.V.4    Pothuri, B.5    Curtin, J.6    Shapira, I.7    Levinson, B.8    Ivy, P.9    Joseph, B.10
  • 97
    • 84879796431 scopus 로고    scopus 로고
    • A phase II study ofgemcitabine and oxaliplatin in advanced transitionalcell carcinoma of the bladder
    • PMID:23636451
    • Eroglu Z, Fruehauf JP. A phase II study ofgemcitabine and oxaliplatin in advanced transitionalcell carcinoma of the bladder. Cancer ChemotherPharmacol 2013; 72:263-7; PMID:23636451; http:// dx.doi.org/10.1007/s00280-013-2178-x
    • (2013) Cancer ChemotherPharmacol , vol.72 , pp. 263-267
    • Eroglu, Z.1    Fruehauf, J.P.2
  • 98
    • 84879795373 scopus 로고    scopus 로고
    • A phase I trial ofoxaliplatin in combination with docetaxel in patientswith advanced solid tumors
    • PMID:23712328
    • Iqbal S, Lenz HJ, Gandara DR, Shibata SI, GroshenS, Synold TW, Newman EM. A phase I trial ofoxaliplatin in combination with docetaxel in patientswith advanced solid tumors. Cancer ChemotherPharmacol 2013; 72:85-91; PMID:23712328; http://dx.doi.org/10.1007/s00280-013-2171-4
    • (2013) Cancer ChemotherPharmacol , vol.72 , pp. 85-91
    • Iqbal, S.1    Lenz, H.J.2    Gandara, D.R.3    Shibata, S.I.4    Groshen, S.5    Synold, T.W.6    Newman, E.M.7
  • 99
    • 84880916267 scopus 로고    scopus 로고
    • A phase II study to evaluate the efficacy and toxicityof oxaliplatin in combination with gemcitabine incarcinoma of unknown primary
    • PMID:22218909
    • Carlson H, Lenzi R, Raber MN, Varadhachary GR. A phase II study to evaluate the efficacy and toxicityof oxaliplatin in combination with gemcitabine incarcinoma of unknown primary. Int J Clin Oncol 2013; 18:226-31; PMID:22218909; http://dx.doi. org/10.1007/s10147-011-0366-4
    • (2013) Int J Clin Oncol , vol.18 , pp. 226-231
    • Carlson, H.1    Lenzi, R.2    Raber, M.N.3    Varadhachary, G.R.4
  • 100
    • 84885615786 scopus 로고    scopus 로고
    • Autophagy-dependent ATP release fromdying cells via lysosomal exocytosis
    • PMID:23989612
    • Wang Y, Martins I, Ma Y, Kepp O, Galluzzi L, Kroemer G. Autophagy-dependent ATP release fromdying cells via lysosomal exocytosis. Autophagy 2013; 9:1624-5; PMID:23989612; http://dx.doi. org/10.4161/auto.25873
    • (2013) Autophagy , vol.9 , pp. 1624-1625
    • Wang, Y.1    Martins, I.2    Ma, Y.3    Kepp, O.4    Galluzzi, L.5    Kroemer, G.6
  • 103
    • 84886943382 scopus 로고    scopus 로고
    • ATP-dependent recruitment, survival and differentiation of dendritic cellprecursors in the tumor bed after anticancerchemotherapy
    • PMID:23894718
    • Ma Y, Adjemian S, Yang H, Catani JP, HannaniD, Martins I, Michaud M, Kepp O, SukkurwalaAQ, Vacchelli E, et al. ATP-dependent recruitment, survival and differentiation of dendritic cellprecursors in the tumor bed after anticancerchemotherapy. Oncoimmunology 2013; 2:e24568; PMID:23894718; http://dx.doi.org/10.4161/ onci.24568
    • (2013) Oncoimmunology , vol.2
    • Ma, Y.1    Adjemian, S.2    Yang, H.3    Catani, J.P.4    Hannani, D.5    Martins, I.6    Michaud, M.7    Kepp, O.8    Sukkurwala, A.Q.9    Vacchelli, E.10
  • 105
    • 84886944722 scopus 로고    scopus 로고
    • Tumor necrosisfactor is dispensable for the success of immunogenicanticancer chemotherapy
    • PMID:23894723
    • Ma Y, Yamazaki T, Yang H, Kepp O, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G. Tumor necrosisfactor is dispensable for the success of immunogenicanticancer chemotherapy. Oncoimmunology 2013; 2:e24786; PMID:23894723; http://dx.doi. org/10.4161/onci.24786
    • (2013) Oncoimmunology , vol.2
    • Ma, Y.1    Yamazaki, T.2    Yang, H.3    Kepp, O.4    Galluzzi, L.5    Zitvogel, L.6    Smyth, M.J.7    Kroemer, G.8
  • 108
    • 84879783969 scopus 로고    scopus 로고
    • ROS-induced autophagy in cancer cells assists inevasion from determinants of immunogenic cell death
    • PMID:23800749
    • Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV, Mathieu C, AgostinisP. ROS-induced autophagy in cancer cells assists inevasion from determinants of immunogenic cell death. Autophagy 2013; 9:1292-307; PMID:23800749; http://dx.doi.org/10.4161/auto.25399
    • (2013) Autophagy , vol.9 , pp. 1292-1307
    • Garg, A.D.1    Dudek, A.M.2    Ferreira, G.B.3    Verfaillie, T.4    Vandenabeele, P.5    Krysko, D.V.6    Mathieu, C.7    Agostinis, P.8
  • 110
    • 84858000639 scopus 로고    scopus 로고
    • Enlightening theimpact of immunogenic cell death in photodynamiccancer therapy
    • PMID:22252132
    • Galluzzi L, Kepp O, Kroemer G. Enlightening theimpact of immunogenic cell death in photodynamiccancer therapy. EMBO J 2012; 31:1055-7; PMID:22252132; http://dx.doi.org/10.1038/ emboj.2012.2
    • (2012) EMBO J , vol.31 , pp. 1055-1057
    • Galluzzi, L.1    Kepp, O.2    Kroemer, G.3
  • 111
    • 84884909735 scopus 로고    scopus 로고
    • Circulating nucleosomesand immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advancedpancreatic cancer undergoing chemotherapy
    • PMID:23729200
    • Wittwer C, Boeck S, Heinemann V, Haas M, StieberP, Nagel D, Holdenrieder S. Circulating nucleosomesand immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advancedpancreatic cancer undergoing chemotherapy. Int JCancer 2013; 133:2619-30; PMID:23729200
    • (2013) Int JCancer , vol.133 , pp. 2619-2630
    • Wittwer, C.1    Boeck, S.2    Heinemann, V.3    Haas, M.4    Stieber, P.5    Nagel, D.6    Holdenrieder, S.7
  • 113
    • 84874943967 scopus 로고    scopus 로고
    • Immunogeniccell death biomarkers HMGB1, RAGE, and DNAseindicate response to radioembolization therapy andprognosis in colorectal cancer patients
    • PMID:23047645
    • Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Immunogeniccell death biomarkers HMGB1, RAGE, and DNAseindicate response to radioembolization therapy andprognosis in colorectal cancer patients. Int J Cancer 2013; 132:2349-58; PMID:23047645; http://dx.doi. org/10.1002/ijc.27894
    • (2013) Int J Cancer , vol.132 , pp. 2349-2358
    • Fahmueller, Y.N.1    Nagel, D.2    Hoffmann, R.T.3    Tatsch, K.4    Jakobs, T.5    Stieber, P.6    Holdenrieder, S.7
  • 115
    • 84890277186 scopus 로고    scopus 로고
    • Continuous 4-1BB co-stimulatory signals for theoptimal expansion of tumor-infiltrating lymphocytesfor adoptive T-cell therapy
    • PMID:24319633
    • Chacon JA, Pilon-Thomas S, Sarnaik AA, RadvanyiLG. Continuous 4-1BB co-stimulatory signals for theoptimal expansion of tumor-infiltrating lymphocytesfor adoptive T-cell therapy. Oncoimmunology 2013; 2:e25581; PMID:24319633; http://dx.doi. org/10.4161/onci.25581
    • (2013) Oncoimmunology , vol.2
    • Chacon, J.A.1    Pilon-Thomas, S.2    Sarnaik, A.A.3    Radvanyi, L.G.4
  • 116
    • 81255138298 scopus 로고    scopus 로고
    • Tumor-derivedautophagosome vaccine: mechanism of crosspresentationand therapeutic efficacy
    • PMID:22068657
    • Li Y, Wang LX, Pang P, Cui Z, Aung S, HaleyD, Fox BA, Urba WJ, Hu HM. Tumor-derivedautophagosome vaccine: mechanism of crosspresentationand therapeutic efficacy. Clin CancerRes 2011; 17:7047-57; PMID:22068657; http:// dx.doi.org/10.1158/1078-0432.CCR-11-0951
    • (2011) Clin CancerRes , vol.17 , pp. 7047-7057
    • Li, Y.1    Wang, L.X.2    Pang, P.3    Cui, Z.4    Aung, S.5    Haley, D.6    Fox, B.A.7    Urba, W.J.8    Hu, H.M.9
  • 117
    • 84867517513 scopus 로고    scopus 로고
    • Sorafenib has potent antitumoractivity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model
    • PMID:22952216
    • Kharaziha P, De Raeve H, Fristedt C, Li Q, GruberA, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, et al. Sorafenib has potent antitumoractivity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. CancerRes 2012; 72:5348-62; PMID:22952216; http:// dx.doi.org/10.1158/0008-5472.CAN-12-0658
    • (2012) CancerRes , vol.72 , pp. 5348-5362
    • Kharaziha, P.1    De Raeve, H.2    Fristedt, C.3    Li, Q.4    Gruber, A.5    Johnsson, P.6    Kokaraki, G.7    Panzar, M.8    Laane, E.9    Osterborg, A.10
  • 118
    • 84863169200 scopus 로고    scopus 로고
    • Targeting of distinctsignaling cascades and cancer-associated fibroblastsdefine the efficacy of Sorafenib against prostatecancer cells
    • PMID:22278289
    • Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, et al. Targeting of distinctsignaling cascades and cancer-associated fibroblastsdefine the efficacy of Sorafenib against prostatecancer cells. Cell Death Dis 2012; 3:e262; PMID:22278289; http://dx.doi.org/10.1038/ cddis.2012.1
    • (2012) Cell Death Dis , vol.3
    • Kharaziha, P.1    Rodriguez, P.2    Li, Q.3    Rundqvist, H.4    Björklund, A.C.5    Augsten, M.6    Ullén, A.7    Egevad, L.8    Wiklund, P.9    Nilsson, S.10
  • 119
    • 84861040329 scopus 로고    scopus 로고
    • AEZS-108: atargeted cytotoxic analog of LHRH for the treatmentof cancers positive for LHRH receptors
    • PMID:22577891
    • Engel J, Emons G, Pinski J, Schally AV. AEZS-108: atargeted cytotoxic analog of LHRH for the treatmentof cancers positive for LHRH receptors. Expert OpinInvestig Drugs 2012; 21:891-9; PMID:22577891; http://dx.doi.org/10.1517/13543784.2012.685128
    • (2012) Expert OpinInvestig Drugs , vol.21 , pp. 891-899
    • Engel, J.1    Emons, G.2    Pinski, J.3    Schally, A.V.4
  • 120
    • 84884915030 scopus 로고    scopus 로고
    • Trabectedin: A drug from thesea that strikes tumor-associated macrophages
    • PMID:23894721
    • Allavena P, Germano G, Belgiovine C, D'IncalciM, Mantovani A. Trabectedin: A drug from thesea that strikes tumor-associated macrophages. Oncoimmunology 2013; 2:e24614; PMID:23894721; http://dx.doi.org/10.4161/onci.24614
    • (2013) Oncoimmunology , vol.2
    • Allavena, P.1    Germano, G.2    Belgiovine, C.3    D'Incalci, M.4    Mantovani, A.5
  • 122
    • 84886944739 scopus 로고    scopus 로고
    • Immune effects of 5-fluorouracil: Ambivalencematters
    • PMID:23802066
    • Ghiringhelli F, Bruchard M, Apetoh L. Immune effects of 5-fluorouracil: Ambivalencematters. Oncoimmunology 2013; 2:e23139; PMID:23802066; http://dx.doi.org/10.4161/ onci.23139
    • (2013) Oncoimmunology , vol.2
    • Ghiringhelli, F.1    Bruchard, M.2    Apetoh, L.3
  • 126
    • 79955810347 scopus 로고    scopus 로고
    • Globalexperience with ixabepilone in breast cancer
    • PMID:21554041
    • Kaklamani VG, Xu BH, Gomez HL. Globalexperience with ixabepilone in breast cancer. Expert Rev Anticancer Ther 2011; 11:683-92; PMID:21554041; http://dx.doi.org/10.1586/ era.11.41
    • (2011) Expert Rev Anticancer Ther , vol.11 , pp. 683-692
    • Kaklamani, V.G.1    Xu, B.H.2    Gomez, H.L.3
  • 127
    • 78650256256 scopus 로고    scopus 로고
    • Patupilone in cancer treatment
    • PMID:21142807
    • Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011; 20:107-17; PMID:21142807; http://dx.doi.org/10.1517/135437 84.2011.542148
    • (2011) Expert Opin Investig Drugs , vol.20 , pp. 107-117
    • Bystricky, B.1    Chau, I.2
  • 128
    • 81255203382 scopus 로고    scopus 로고
    • Induction of immunogenic apoptosis by blockadeof epidermal growth factor receptor activation witha specific antibody
    • PMID:21984704
    • Garrido G, Rabasa A, Sánchez B, López MV, BlancoR, López A, Hernández DR, Pérez R, Fernández LE. Induction of immunogenic apoptosis by blockadeof epidermal growth factor receptor activation witha specific antibody. J Immunol 2011; 187:4954-66; PMID:21984704; http://dx.doi.org/10.4049/ jimmunol.1003477
    • (2011) J Immunol , vol.187 , pp. 4954-4966
    • Garrido, G.1    Rabasa, A.2    Sánchez, B.3    López, M.V.4    Blanco, R.5    López, A.6    Hernández, D.R.7    Pérez, R.8    Fernández, L.E.9
  • 129
    • 18744390084 scopus 로고    scopus 로고
    • Cetuximab
    • PMID:15962524
    • Goldberg RM. Cetuximab. Nat Rev Drug Discov 2005; (Suppl): S10-1; PMID:15962524; http:// dx.doi.org/10.1038/nrd1728
    • (2005) Nat Rev Drug Discov , Issue.SUPPL.
    • Goldberg, R.M.1
  • 131
    • 41349111281 scopus 로고    scopus 로고
    • Erlotinib exhibits antineoplastic off-targeteffects in AML and MDS: a preclinical study
    • PMID:17925489
    • Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de BottonS, et al. Erlotinib exhibits antineoplastic off-targeteffects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi. org/10.1182/blood-2007-07-100362
    • (2008) Blood , vol.111 , pp. 2170-2180
    • Boehrer, S.1    Adès, L.2    Braun, T.3    Galluzzi, L.4    Grosjean, J.5    Fabre, C.6    Le Roux, G.7    Gardin, C.8    Martin, A.9    de Botton, S.10
  • 132
    • 34447136111 scopus 로고    scopus 로고
    • A novel epidermal growthfactor receptor inhibitor promotes apoptosis in nonsmallcell lung cancer cells resistant to erlotinib
    • PMID:17616683
    • de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, LazarV, Dessen P, Harper F, et al. A novel epidermal growthfactor receptor inhibitor promotes apoptosis in nonsmallcell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07-0538
    • (2007) Cancer Res , vol.67 , pp. 6253-6262
    • de La Motte Rouge, T.1    Galluzzi, L.2    Olaussen, K.A.3    Zermati, Y.4    Tasdemir, E.5    Robert, T.6    Ripoche, H.7    Lazar, V.8    Dessen, P.9    Harper, F.10
  • 133
    • 84886944764 scopus 로고    scopus 로고
    • Following up tumor-specific regulatory T cells incancer patients
    • PMID:24073383
    • Zitvogel L, Tanchot C, Granier C, Tartour E. Following up tumor-specific regulatory T cells incancer patients. Oncoimmunology 2013; 2:e25444; PMID:24073383; http://dx.doi.org/10.4161/ onci.25444
    • (2013) Oncoimmunology , vol.2
    • Zitvogel, L.1    Tanchot, C.2    Granier, C.3    Tartour, E.4
  • 134
    • 84876990066 scopus 로고    scopus 로고
    • Immunomonitoring and prognosticrelevance of neutrophils in clinical trials
    • PMID:23403174
    • Donskov F. Immunomonitoring and prognosticrelevance of neutrophils in clinical trials. SeminCancer Biol 2013; 23:200-7; PMID:23403174; http://dx.doi.org/10.1016/j.semcancer.2013.02.001
    • (2013) SeminCancer Biol , vol.23 , pp. 200-207
    • Donskov, F.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.